Nintedanib Eugia

Nintedanib, the active ingredient in Nintedanib Eugia, is a tyrosine kinase inhibitor presented as an oral formulation for oral use. It treats idiopathic pulmonary fibrosis, systemic sclerosis‑associated interstitial lung disease, and is used in combination therapy for non‑small cell lung cancer in appropriate patients.

GNH USA supplies Nintedanib Eugia as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, oncology centres, pharmacies and clinics worldwide.

Nintedanib acts on fibrotic and oncogenic pathways to modify disease progression. - Idiopathic pulmonary fibrosis (IPF): slows decline in lung function and disease progression. - Systemic sclerosis‑associated interstitial lung disease (SSc‑ILD): helps preserve lung capacity and delays worsening. - Non‑small cell lung cancer (NSCLC) in combination therapy: contributes to tumor control when used with other anticancer agents.

Nintedanib may cause a range of adverse reactions, which are generally categorized by frequency and severity.

Common Side Effects: - Diarrhea: frequent loose stools. - Nausea: feeling sick. - Decreased appetite: reduced desire to eat. - Elevated liver enzymes: increase in ALT/AST.

Serious or Rare Side Effects: - Hepatotoxicity: severe liver injury, may cause jaundice. - Bleeding events: gastrointestinal or other hemorrhage. - Cardiovascular events: arterial thromboembolism or myocardial infarction.

Before initiating therapy, clinicians should evaluate several safety parameters. - Monitor liver function: perform baseline and periodic ALT/AST tests. - Assess bleeding risk: avoid in patients with active ulcers or anticoagulant therapy without supervision. - Evaluate cardiovascular status: caution in patients with history of arterial thromboembolism. - Review concomitant medications: consider potential interactions with CYP3A4 inhibitors/inducers. - Pregnancy and lactation: avoid use; safety not established. - Store at ambient temperature: keep below 25 °C, in original packaging, protect from moisture.

Nintedanib can interact with other medicines, requiring careful management.

Major Interactions (Avoid): - Strong CYP3A4 inhibitors (e.g., ketoconazole, clarithromycin): may increase nintedanib exposure. - Anticoagulants (warfarin, direct oral anticoagulants): heightened bleeding risk. - Antiplatelet agents (aspirin, clopidogrel): increased hemorrhage potential.

Moderate Interactions (Monitor Closely): - Moderate CYP3A4 inhibitors (e.g., fluconazole): may modestly raise levels. - CYP3A4 inducers (e.g., rifampicin, carbamazepine): may reduce efficacy. - P‑glycoprotein inhibitors (e.g., verapamil): possible increased exposure.